Published in J Am Med Inform Assoc on August 26, 2013
Pharmacogenomics in the clinic. Nature (2015) 1.71
Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing. Genet Med (2015) 1.59
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet (2014) 1.49
Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers Med (2014) 1.26
CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. J Am Med Inform Assoc (2015) 1.20
Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet (2014) 1.19
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med (2016) 1.16
Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther (2013) 1.10
Integrating pharmacogenetic information and clinical decision support into the electronic health record. J Am Med Inform Assoc (2013) 0.98
The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information. J Pers Med (2013) 0.97
Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians. J Biomed Inform (2015) 0.96
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst (2014) 0.94
Closing the gap between knowledge and clinical application: challenges for genomic translation. PLoS Genet (2015) 0.94
Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther (2016) 0.87
Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality. Am J Med (2016) 0.85
Clinician Perspectives on Using Pharmacogenomics in Clinical Practice. Per Med (2015) 0.84
A proposed clinical decision support architecture capable of supporting whole genome sequence information. J Pers Med (2014) 0.83
Practical considerations in genomic decision support: The eMERGE experience. J Pathol Inform (2015) 0.82
Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J (2015) 0.81
Trends in biomedical informatics: automated topic analysis of JAMIA articles. J Am Med Inform Assoc (2015) 0.81
Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now. Pharm Res (2017) 0.81
Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm (2016) 0.79
Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. CMAJ Open (2016) 0.78
Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med (2016) 0.78
Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform (2015) 0.77
Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet (2015) 0.77
Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project. AMIA Annu Symp Proc (2015) 0.77
Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association. Circ Cardiovasc Genet (2016) 0.77
A brighter future for the implementation of pharmacogenomic testing. Eur J Hum Genet (2016) 0.75
An inter-professional approach to personalized medicine education: one institution's experience. Per Med (2015) 0.75
Integrating electronic health record genotype and phenotype datasets to transform patient care. Clin Pharmacol Ther (2016) 0.75
Computerized Clinical Decision Support: Contributions from 2014. Yearb Med Inform (2015) 0.75
Evaluation: A Qualitative Pilot Study of Novel Information Technology Infrastructure to Communicate Genetic Variant Updates. Appl Clin Inform (2016) 0.75
Novel Disease-Drug Database Demonstrating Applicability for Pharmacogenomic-Based Prescribing. Clin Pharmacol Ther (2016) 0.75
Prevalence of clinically actionable genotypes and medication exposure of older adults in the community. Pharmgenomics Pers Med (2017) 0.75
Pragmatic and Ethical Challenges of Incorporating the Genome into the Electronic Medical Record. Curr Genet Med Rep (2014) 0.75
Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet Genomics (2017) 0.75
Design Recommendations for Pharmacogenomics Clinical Decision Support Systems. AMIA Jt Summits Transl Sci Proc (2017) 0.75
Characterizing pharmacogenomic-guided medication use with a clinical data repository. Clin Pharmacol Ther (2017) 0.75
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther (2017) 0.75
Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med (2003) 12.98
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther (2011) 10.95
Logical observation identifier names and codes (LOINC) database: a public use set of codes and names for electronic reporting of clinical laboratory test results. Clin Chem (1996) 9.21
Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc (2005) 8.87
LOINC, a universal standard for identifying laboratory observations: a 5-year update. Clin Chem (2003) 8.46
Development of the Logical Observation Identifier Names and Codes (LOINC) vocabulary. J Am Med Inform Assoc (1998) 6.73
A roadmap for national action on clinical decision support. J Am Med Inform Assoc (2007) 6.48
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
Overrides of medication alerts in ambulatory care. Arch Intern Med (2009) 4.24
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Effect of clinical decision-support systems: a systematic review. Ann Intern Med (2012) 3.42
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther (2012) 3.15
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther (2013) 2.38
Effects of clinical decision-support systems on practitioner performance and patient outcomes: a synthesis of high-quality systematic review findings. J Am Med Inform Assoc (2011) 2.12
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia (2009) 2.11
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia (2009) 1.99
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther (2012) 1.88
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Evaluating clinical decision support systems: monitoring CPOE order check override rates in the Department of Veterans Affairs' Computerized Patient Record System. J Am Med Inform Assoc (2008) 1.78
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther (2012) 1.72
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Pharmacogenetics: from bench to byte. Clin Pharmacol Ther (2008) 1.40
Clinical decision support for genetically guided personalized medicine: a systematic review. J Am Med Inform Assoc (2012) 1.26
Recommended practices for computerized clinical decision support and knowledge management in community settings: a qualitative study. BMC Med Inform Decis Mak (2012) 1.17
Safe and successful implementation of CPOE for chemotherapy at a children's cancer center. J Natl Compr Canc Netw (2011) 0.92
A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther (2013) 0.91
Multiple perspectives on the meaning of clinical decision support. AMIA Annu Symp Proc (2010) 0.87
The need for collaborative engagement in creating clinical decision-support alerts. Am J Health Syst Pharm (2013) 0.85
Building an innovative model for personalized healthcare. Cleve Clin J Med (2012) 0.83
Clinical implementation of pharmacogenetics: more than one gene at a time. Clin Pharmacol Ther (2013) 0.82
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med (2011) 9.03
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57
An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med (2009) 3.56
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol (2011) 3.05
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction. Circulation (2005) 2.81
Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. Lancet Oncol (2008) 2.49
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet (2009) 2.37
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy (2009) 2.31
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer (2013) 2.23
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol (2008) 2.14
Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet (2003) 2.00
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet (2005) 1.94
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer (2005) 1.93
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85